These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 37079081)

  • 1. The 10th International Conference on cGMP 2022: recent trends in cGMP research and development-meeting report.
    Friebe A; Kraehling JR; Russwurm M; Sandner P; Schmidtko A
    Naunyn Schmiedebergs Arch Pharmacol; 2023 Aug; 396(8):1669-1686. PubMed ID: 37079081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. cGMP: a unique 2nd messenger molecule - recent developments in cGMP research and development.
    Friebe A; Sandner P; Schmidtko A
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Feb; 393(2):287-302. PubMed ID: 31853617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The nitric oxide-soluble guanylate cyclase-cGMP pathway in pulmonary hypertension: from PDE5 to soluble guanylate cyclase.
    Benza RL; Grünig E; Sandner P; Stasch JP; Simonneau G
    Eur Respir Rev; 2024 Jan; 33(171):. PubMed ID: 38508664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meeting report of the 8
    Friebe A; Sandner P; Schmidtko A
    Naunyn Schmiedebergs Arch Pharmacol; 2017 Dec; 390(12):1177-1188. PubMed ID: 29018913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators.
    Sandner P
    Biol Chem; 2018 Jun; 399(7):679-690. PubMed ID: 29604206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. cGMP: transition from bench to bedside: a report of the 6th International Conference on cGMP Generators, Effectors and Therapeutic Implications.
    Hoffmann LS; Chen HH
    Naunyn Schmiedebergs Arch Pharmacol; 2014 Aug; 387(8):707-18. PubMed ID: 24927824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble Guanylate Cyclase Stimulators and Activators.
    Sandner P; Zimmer DP; Milne GT; Follmann M; Hobbs A; Stasch JP
    Handb Exp Pharmacol; 2021; 264():355-394. PubMed ID: 30689085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure.
    Breitenstein S; Roessig L; Sandner P; Lewis KS
    Handb Exp Pharmacol; 2017; 243():225-247. PubMed ID: 27900610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure.
    Triposkiadis F; Xanthopoulos A; Skoularigis J; Starling RC
    Heart Fail Rev; 2022 Nov; 27(6):1991-2003. PubMed ID: 35437713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homogeneous single-label cGMP detection platform for the functional study of nitric oxide-sensitive (soluble) guanylyl cyclases and cGMP-specific phosphodiesterases.
    Kopra K; Sharina I; Martin E; Härmä H
    Sci Rep; 2020 Oct; 10(1):17469. PubMed ID: 33060787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From bedside to bench--meeting report of the 7th International Conference on cGMP "cGMP: generators, effectors and therapeutic implications" in Trier, Germany, from June 19th to 21st 2015.
    Friebe A; Sandner P; Seifert R
    Naunyn Schmiedebergs Arch Pharmacol; 2015 Dec; 388(12):1237-46. PubMed ID: 26486926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble Guanylate Cyclase Stimulators and Activators: Novel Therapies for Pulmonary Vascular Disease or a Different Method of Increasing cGMP?
    Koress C; Swan K; Kadowitz P
    Curr Hypertens Rep; 2016 Apr; 18(5):42. PubMed ID: 27118316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of cGMP in heart failure: a new therapeutic paradigm.
    Boerrigter G; Lapp H; Burnett JC
    Handb Exp Pharmacol; 2009; (191):485-506. PubMed ID: 19089342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble Guanylyl Cyclase Activators-Promising Therapeutic Option in the Pharmacotherapy of Heart Failure and Pulmonary Hypertension.
    Grześk G; Witczyńska A; Węglarz M; Wołowiec Ł; Nowaczyk J; Grześk E; Nowaczyk A
    Molecules; 2023 Jan; 28(2):. PubMed ID: 36677920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. cGMP becomes a drug target.
    Schlossmann J; Schinner E
    Naunyn Schmiedebergs Arch Pharmacol; 2012 Mar; 385(3):243-52. PubMed ID: 22297800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Impact of the Nitric Oxide (NO)/Soluble Guanylyl Cyclase (sGC) Signaling Cascade on Kidney Health and Disease: A Preclinical Perspective.
    Krishnan SM; Kraehling JR; Eitner F; Bénardeau A; Sandner P
    Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29890734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erectile Dysfunction in Heme-Deficient Nitric Oxide-Unresponsive Soluble Guanylate Cyclase Knock-In Mice.
    Decaluwé K; Pauwels B; Boydens C; Thoonen R; Buys ES; Brouckaert P; Van de Voorde J
    J Sex Med; 2017 Feb; 14(2):196-204. PubMed ID: 28161078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Endothelium-Dependent Nitric Oxide-cGMP Pathway.
    Mónica FZ; Bian K; Murad F
    Adv Pharmacol; 2016; 77():1-27. PubMed ID: 27451093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble guanylate cyclase stimulators in pulmonary hypertension.
    Stasch JP; Evgenov OV
    Handb Exp Pharmacol; 2013; 218():279-313. PubMed ID: 24092345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble guanylate cyclase stimulator praliciguat attenuates inflammation, fibrosis, and end-organ damage in the Dahl model of cardiorenal failure.
    Shea CM; Price GM; Liu G; Sarno R; Buys ES; Currie MG; Masferrer JL
    Am J Physiol Renal Physiol; 2020 Jan; 318(1):F148-F159. PubMed ID: 31608671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.